Due to the shift of care from hospital to home and increasing prevalence of obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD), the global market value for positive airway pressure (PAP) devices, currently estimated at $1.8bn, is expected to expand to $3.5bn by 2028 at a compound annual growth rate (CAGR) of 7.7%.
PAP devices are commonly used in hospitals and long-term care facilities and have become more popular in home settings. By applying continuous, bi-level, intermittent or expiratory positive airway pressure, they provide spontaneously breathing patients with short-term mechanical assistance. However, they are not designed to be life support devices and are not intended to replace advanced mechanical ventilators.
Positive airway pressure devices can improve nocturnal alveolar hypoventilation for patients with COPD and / or OSA. Non-invasive ventilation at home improves the quality and tolerance of the treatment. Additionally, it can reduce healthcare costs associated with the management of patients with severe COPD by greatly increasing the time between hospital readmissions.
Product innovation is the other driver for the market and further increases the adoption in home settings. As patient compliance has been a major factor in the efficacy of PAP treatment, products with improved patient comfort and compliance have been developed. These include more comfortable patient interface systems, delay timers that gradually raise air pressure, allowing the patient to fall asleep more easily, bi-level air devices, including variable positive airway pressure systems that provide different air pressures for inhalation and exhalation, heated humidification systems to make the airflow more comfortable, and auto-titration devices that reduce the average pressure delivered during the night. Furthermore, the size of the devices becomes smaller to allow patients to use them during travel.
Home care use of PAP devices will be more prevalent. The home care devices reduce the burden on healthcare systems and improve patients’ compliance by developing products that are more user-friendly and effective. With the increasing awareness of diseases and devices, GlobalData believes the home market of PAP devices will be experiencing robust growth globally through 2028.